Elmira Mostafidi
1,2, Bahareh Mehramuz
1,2, Mohammad Reza Ardalan
2*1 Department of Pathology, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
2 Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Abstract
Kidney involvement in cancer patients is an increasing problem that needs more complex, collaborative and specialized care. Increasing number of patients are treated with new classes of medications that predispose them to kidney injury. With increasing the population age of cancer patients who are already at increased risk for kidney disease, emerging kidney toxicities associated with drugs targeting VEGF and other signaling pathways are problems that nowadays we are facing for management of these patients. Myeloma- associated kidney disease, cancer and treatment-related microangiopathies and glomerulonephritis, stem cell transplant-associated kidney injuries, all are exciting and expanding horizons in this field.